Browse

You are looking at 281 - 290 of 330 items for :

  • Special Section x
  • Refine by Content Type: Articles x
Clear All Modify Search

One simple, no-cost change appears to lower cardiovascular (CV) risk among patients with resistant hypertension. By taking their antihypertensive medications at bedtime instead of in the morning, patients in a Spanish trial significantly reduced their cardiovascular risk.

Researchers have known that sleep-time blood pressure (BP) better predicts CV risk than does either the awake or 24-hour BP means. However, all previous studies relied on a single baseline ambulatory blood pressure monitoring (ABPM) profile on each participant at the beginning of the study. Thus, they could not detect changes in the pattern or level of BP if they occurred.

Reporting at

Daniel M. Keller

With the incidence and prevalence of cardiovascular disease (CVD) increasing worldwide and its connection to chronic kidney disease (CKD), the new president of the European Renal Association – European Dialysis and Transplant Association outlined in a news conference at the association’s 48th Congress in Prague several steps by which physicians can help to alleviate the personal and economic burdens of CVD. CVD is responsible for about 10 percent of all illness and 30 percent of all deaths in the world.

Raymond Vanholder, MD, PhD, professor of medicine at the University of Ghent and clinical head of the nephrology division of

Daniel M. Keller

A single 4-week course of rituximab was as effective as 18 months of standard therapy with daily oral cyclophosphamide (CyP) and azathioprine (AZA) for induction of remission and maintenance therapy of severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The number, rate, and severity of adverse events was similar between the treatment groups, Cees Kallenberg, MD, PhD, professor of clinical immunology at University Medical Center Groningen in Groningen, Netherlands, reported at the 48th Congress of the European Renal Association-European Dialysis and Transplant Association in Prague in June. Rituximab is a monoclonal antibody directed against B lymphocytes.

AAV, an autoimmune disease, affects

Richard Lafayette

During pregnancy, the development of acute renal failure is especially daunting because two lives are involved and at risk. The outcomes of acute kidney injury (AKI), as in other settings, can be quite poor, with significant morbidity and mortality rates of 20–30 percent.

Variable definitions of AKI have been used for pregnancy. The normal baseline serum creatinine during pregnancy is approximately 0.5 mg/dL; thus, a rise over 48 hours to values greater than 1.0 mg/dL, or an increase from a baseline of more than 0.5 mg/dL in 48 hours, should trigger further evaluation for AKI. It has been suggested that

Sharon E. Maynard

Pre-eclampsia is a systemic syndrome occurring in the second half of pregnancy, with cardinal manifestations of hypertension and proteinuria. Pre-eclampsia is one of the most common glomerular diseases in the world; it affects approximately 3–5 percent of all pregnancies. Although careful obstetric management—including antihypertensive medications and seizure prophylaxis with intravenous magnesium—is important for the treatment of pre-eclampsia, delivery of the neonate and placenta remains the only definitive treatment. Thus, pre-eclampsia remains a leading cause of maternal mortality, preterm birth, and consequent neonatal morbidity and mortality. In developing countries, where access to safe, emergent delivery is less readily available, pre-eclampsia claims

Michelle Hladunewich

About 5 percent of pregnancies suffer complications from abnormal placental development. The process of placentation begins when blastocysts adhere to the uterine endometrium, forming a lineage of epithelial cells termed the invasive extravillous cytotrophoblast, which then invades the uterine wall to create the decidua, transforming the spiral arteries into a low-resistance uteroplacental circulation.

Impaired development of the uteroplacental vasculature, therefore, has its origins in the first trimester as a result of an abnormal interaction between the invading extravillous cytotrophoblast and the maternal immune system, resulting in decidual vasculopathy, with small, poorly developed spiral arteries. As these pregnancies progress, placental ischemia

In this month’s issue, ASN Kidney News editorial board member Edgar Lerma interviewed Susan Hou, MD, of the division of nephrology at Loyola University Medical Center.

Dianne B. McKay and Michelle A. Josephson

The Nobel Laureate Joseph Murray provided the first report of pregnancy in a transplant recipient (1). Since that time, over 16,000 pregnancies have been documented in the world literature (2). Many more pregnancies have clearly occurred, now that pregnancy after transplantation is commonplace and is rarely reported. The data about pregnancy in transplant recipients come from case reports and registry reports, but these sources underrepresent the population of transplant recipients who have become pregnant (2).

This review relies on data from registry reports in the United States, the United Kingdom, and Europe, but we

Phyllis August
Healthy kidneys—healthy pregnancy

A healthy pregnancy—a baby born at term, with minimal untoward physical consequences to the mother—is the ideal outcome and indeed, when it occurs, is nothing short of a miracle. That the maternal kidneys are such important players in this process is perhaps not news to the seasoned nephrologist, but it is a concept that bears emphasizing, particularly when a woman with kidney disease or even hypertension contemplates pregnancy. Why this should be so is likely a result of the critical role of the kidneys in adapting the circulation to the increasing demands of the conceptus, and accommodating

Daniel M. Keller

Even with protocols in place to improve compliance, many kidney transplant patients did not achieve risk factor targets for cardiovascular disease, a leading cause of graft failure and of death after transplantation, according to study results presented at the American Transplant Congress in Philadelphia in early May. But as time went on after transplantation, the modifiable risk factors of hypertension, hyperlipidemia, and diabetes mellitus could become better controlled, said lead author Rakesh Kumar, MD, of the State University of New York at Buffalo.

Although advances in immunosuppressive therapy can prevent immune-mediated damage to transplanted kidneys and improve short-term allograft survival,